Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
T414199-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$84.90
|
|
|
T414199-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$296.90
|
|
|
T414199-10mg
|
10mg |
3
|
$494.90
|
|
|
T414199-25mg
|
25mg |
2
|
$1,038.90
|
|
|
T414199-50mg
|
50mg |
2
|
$1,484.90
|
|
|
T414199-100mg
|
100mg |
1
|
$2,375.90
|
|
EGFR/ErbB1 Selective Inhibitors | Activators
| Synonyms | 1661854-97-2 | AS-79368 | D93895 | 2-Propenamide, N-((8S)-4-amino-8,9-dihydro-6-methyl-5-(3-quinolinyl)pyrimido(5,4-b)indolizin-8-yl)- | tert-butoxycarbonylamino-(dimethoxy-phosphoryl)-acetic acid methyl ester | AKOS040742682 | CLN-081 | MKCYPWYURWOKST-IN |
|---|---|
| Specifications & Purity | Moligand™, ≥99% |
| Biochemical and Physiological Mechanisms | TAS6417 (CLN-081, TPC-064) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L. |
| Storage Temp | Protected from light,Store at -20°C,Argon charged |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Action Type | INHIBITOR |
| Mechanism of action | Epidermal growth factor receptor erbB1 inhibitor |
| Product Description |
Information TAS6417 (CLN-081, TPC-064) is a novelEGFRinhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L. Targets EGFR(d746-750/T790M) (Cell-free assay); TXK (Cell-free assay); EGFR(d746-750) (Cell-free assay); EGFR L858R (Cell-free assay); EGFR T790M/L858R (Cell-free assay) 31954,1.1 nM; 1.1 nM; 1.4 nM; 1.9 nM; 2 nM In vitro Of the 255 kinases tested, TAS6417 inhibits 25 kinases other than EGFR with IC50 values less than 1,000 nmol/L, which was 100 times higher than its IC50 value against WT EGFR. It inhibits only six kinases containing TXK, BMX, HER4, TEC, BTK, and JAK3, with IC50 values less than 10 times that against WT EGFR. TAS6417 inhibits proliferation of Ba/F3 cells driven by various EGFR exon 20 insertion mutations, with IC50 values ranging from 5.05 ± 1.33 nmol/L to 150 ± 53 nmol/L. It also suppresses the growth of cells expressing exon 20 insertion mutations of the EGFR gene, with a GI50 value of 86.5 ± 28.5 nmol/L for LXF 2478L cells and 45.4 ± 2.6 nmol/L for NCI-H1975 EGFR D770_N771insSVD cells. TAS6417 has no effect on EGFR-independent proliferation in NCI-H23 or NCI-H460 cells. In vivo TAS6417 causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models. The tumor regression occurrs quickly after TAS6417 treatment and persists during the treatment period. Pharmacokinetic analysis reveals that the plasma concentration of TAS6417, administered at 50 and 100 mg/kg to mice, decreases rapidly in the first 4 hours. In contrast, although the effective doses in the rat model exhibit lower maximum plasma concentration (Cmax) values than those in the mouse model, the plasma concentrations tend to be more persistent, lasting up to 8 hours. TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. It prolongs survival of animals bearing lung cancer. Cell Research(from reference) Cell lines:LXF 2478L cells and NCI-H1975 EGFR D770_N771insSVD cells Concentrations:0-1 μM Incubation Time:6 and 24 hours |
| ALogP | 3.124 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 3 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504772840 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504772840 |
| IUPAC Name | N-[(8S)-4-amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide |
| INCHI | InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1 |
| InChIKey | MKCYPWYURWOKST-INIZCTEOSA-N |
| Smiles | CC1=CC(CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C |
| Isomeric SMILES | CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C |
| PubChem CID | 117918742 |
| Molecular Weight | 396.44 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | May 09, 2025 | T414199 | |
| Certificate of Analysis | May 09, 2025 | T414199 | |
| Certificate of Analysis | May 09, 2025 | T414199 | |
| Certificate of Analysis | May 09, 2025 | T414199 |
| Solubility | Solubility (25°C) In vitro DMSO: 79 mg/mL (199.27 mM); Ethanol: 79 mg/mL (199.27 mM); Water: Insoluble; |
|---|---|
| Sensitivity | Light sensitive |
| DMSO(mg / mL) Max Solubility | 79 |
| DMSO(mM) Max Solubility | 199.273534456664 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 396.400 g/mol |
| XLogP3 | 2.300 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 396.17 Da |
| Monoisotopic Mass | 396.17 Da |
| Topological Polar Surface Area | 98.700 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 710.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |